Use of colchicine to inhibit tumor growth and metastases

11534,415

16/966892

February 01, 2019

Use of colchicine to inhibit tumor growth and metastases in mammalian subjects comprising the administration of the compositions and formulations are provided. The described colchicine compositions and formulations include sustained release, and multimodal release compositions and formulations suitable for alone or in combination with additional pharmaceutically active agents useful in treating tumor growth and metastases.

Murray and Poole Enterprises, LTD. (Gibraltar, GB)

MURRAY AND POOLE ENTERPRISES LTD (Gibraltar, GI)

1. A method for inhibiting, delaying, or reducing tumor growth or metastases or both tumor growth and metastases in a subject diagnosed with or suffering from cancer, comprising administering to the subject a sustained release formulation comprising: (a) granules comprising between 0.1 mg to 0.60 mg of colchicine or a pharmaceutically acceptable salt thereof; (b) a binder, wherein the binder is hydroxypropyl methylcellulose (HPMC) 6 mPa·s in an amount of 1% to 30% (w/w) of the formulation; (c) a retarding agent in an amount of 5% to 40% (w/w) of the formulation, wherein the retarding agent is a spray agglomerated blend of equal parts by weight of HPMC with a viscosity grade of 4000 mPa·s and lactose monohydrate; and (d) at least one pharmaceutically acceptable excipient blended with the granules, wherein the sustained release formulation is a tablet.

2. The method of claim 1 , wherein colchicine induces anti-tumor responses.

3. The method of claim 1 , wherein colchicine inhibits IL-1β mediated signaling.

4. The method of claim 1 , wherein colchicine inhibits inflammation activation.

5. The method of claim 1 , wherein colchicine inhibits release of TNF-α and IL-10.

6. The method of claim 1 , wherein the inhibition, delay, or reduction of metastases occurs independently of primary tumor growth inhibition, delay, or reduction.

7. The method of claim 1 , wherein colchicine is included in an amount between about 0.5 mg and about 0.60 mg.

8. The method of claim 1 , wherein colchicine is included in an amount of 0.55 mg.

9. The method of claim 1 , wherein the cancer is one or more of carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, and head and neck cancer.

10. A method for inhibiting, delaying, or reducing tumor growth or metastases or both tumor growth and metastases in a subject diagnosed with or suffering from cancer, comprising administering to the subject a sustained release formulation comprising: (a) granules comprising between 0.1 mg to 0.60 mg of colchicine or a pharmaceutically acceptable salt thereof; (b) a binder, wherein the binder is hydroxypropyl methylcellulose (HPMC) 6 mPa·s in an amount of 1% to 30% (w/w) of the formulation; (c) a retarding agent in an amount of 5% to 40% (w/w) of the formulation, wherein the retarding agent is a spray agglomerated blend of equal parts by weight of HPMC with a viscosity grade of 4000 mPa·s and lactose monohydrate; and (d) at least one pharmaceutically acceptable excipient blended with the granules, wherein the sustained release formulation is a tablet, and an effective amount of at least one other immune modulating agent or immune modulating therapy.

11. The method of claim 10 , wherein colchicine induces anti-tumor responses.

12. The method of claim 10 , wherein colchicine inhibits IL-1β mediated signaling.

13. The method of claim 10 , wherein colchicine inhibits release of TNF-α and IL-10.

14. The method of claim 10 , wherein colchicine inhibits inflammation activation.

15. The method of claim 10 , wherein the inhibition, delay, or reduction of metastases occurs independently of primary tumor growth inhibition, delay, or reduction.

16. The method of claim 10 , wherein colchicine is included in an amount between about 0.5 mg and about 0.60 mg.

17. The method of claim 10 , wherein colchicine is included in an amount of 0.55 mg.

18. The method of claim 10 , wherein the cancer is one or more of carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, and head and neck cancer.

19. The method of claim 10 , wherein the immune modulating agent is one or more of interleukins, cytokines, chemokines, and antagonists of immune checkpoint blockades.

20. The method of claim 10 , wherein the immune modulating therapy is a cancer therapy.

21. The method of claim 20 , wherein the cancer therapy is one or more of surgery or surgical procedures, radiation therapy, and chemotherapy.

22. The method of claim 10 , wherein colchicine and the immune modulating agent or immune modulating therapy are administered separately or concurrently.

1748671 March 2006
101485637 July 2009
2014066944 May 2014
2014/170755 October 2014
2015/069770 May 2015

Zu-Yan Lin et al., “Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines”, The Kaohsiung Journal of Medical Sciences, vol. 32, 2016, pp. 68-73. cited by applicant
Asli Muvaffak et al., “Prolonged Cytotoxic Effect of Colchicine Released from Biodegradable Microspheres”, Journal of Biomedical Materials Research Part B: Applied Biomaterials: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, vol. 71, No. 2, pp. 295-304. cited by applicant
International Search Report and Written Opinion, dated May 24, 2019, PCT International Application No. PCT/EP2019/052492, pp. 1-16. cited by applicant

edspgr.11534415